Collapse temperature is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
A formulation often contains excipients that protect the active ingredient during freezing and drying. Bulking agents provide structure, while lyoprotectants stabilize sensitive molecules. The freezing step can produce ice crystals whose size and distribution affect the drying rate, and cycle design includes freezing, annealing, and drying phases. If the product temperature rises above a critical value, the cake may collapse or lose its porous structure. Successful lyophilization therefore depends on the interaction between formulation, equipment, and cycle design.
Lyophilization is a dehydration process that removes water from a frozen material by sublimation under low pressure. The material is first frozen to convert liquid water into ice. Next, the pressure is reduced below the triple point of water so that ice changes directly into vapor without passing through a liquid phase. This step is called primary drying. The result is a porous solid or cake that retains the original shape of the frozen solution.
Quality control for lyophilized products includes appearance, cake structure, reconstitution time, pH, residual moisture, and potency. Residual moisture is a key attribute because excess water can reduce stability, while excessively low moisture may cause structural changes or aggregation in some systems. Stability studies compare real-time and accelerated conditions to estimate shelf life. Analytical methods must be validated for the specific matrix, container, and moisture range. Sterility and container integrity are also monitored for sterile products.
Handling practices aim to prevent moisture ingress and mechanical damage. Vials should remain stoppered and crimped until use, and reconstitution should follow the labeled diluent and volume. Shipping may involve temperature-controlled containers and desiccants, but direct contact between desiccant and product is avoided. Regulatory guidance expects documented storage conditions, excursion assessments, and stability commitments. Open questions remain about how best to predict long-term stability from short accelerated studies for every formulation class.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Freeze-drying, lyophilisation | Lyophilization is the American spelling; lyophilisation is British |
| Primary drying mechanism | Sublimation of ice | Occurs under vacuum below the triple point |
| Typical chamber pressure | 0.05-0.5 mbar | Range depends on product and equipment |
| Typical shelf temperature during freezing | -40 to -20 °C | Lower temperatures may be used for labile products |
| Resulting product form | Porous cake or powder | Appearance depends on formulation and cycle |
The physics of freeze-drying couples heat transfer, mass transfer, and phase change. Heat supplied through the shelf must reach the sublimation front without melting the ice or degrading the product. Water vapor then travels through the already dried layer and leaves the chamber, where low pressure and cold traps keep it from returning. The dried layer acts as a resistance to vapor flow, so drying rate changes as the front recedes. Open questions remain about how pore structure and formulation heterogeneity affect drying uniformity at larger scales.
Lyophilization removes water from a frozen material by sublimation under reduced pressure. The process begins with freezing, which converts liquid water into ice and concentrates dissolved solids. Primary drying then lowers chamber pressure so ice changes directly into vapor without passing through a liquid phase. Secondary drying raises the shelf temperature to remove bound water that remains after ice sublimation. The result is a dry, porous structure that can be reconstituted later.
Quality control for lyophilized materials examines appearance, reconstitution time, residual moisture, and mechanical integrity. An acceptable cake is usually uniform and porous, though appearance alone does not prove stability. Karl Fischer titration is a common method for water content, while differential scanning calorimetry can reveal glass transition events. Stability studies track potency, aggregation, and moisture over time under defined temperature and humidity conditions. Specifications are product-specific and may include sterility and endotoxin tests for sterile preparations.
Misconceptions about lyophilization include the idea that dried products are indefinitely stable or that vacuum sealing eliminates all degradation. Chemical reactions can continue in the solid state, and some proteins lose activity even at low moisture. Another misconception is that any freeze-dryer cycle can be scaled by time alone; heat and mass transfer differ with equipment and load. Open questions remain about predicting long-term stability from short accelerated studies, particularly for amorphous formulations. Real-time stability data remain the standard for shelf-life assignment.
Industries use lyophilization for pharmaceuticals, biological products, and food preservation. In the pharmaceutical sector, it extends the shelf life of injectable drugs, vaccines, and proteins that are unstable in aqueous solution. Food manufacturers apply freeze-drying to coffee, fruits, and ready meals to retain flavor and texture. The process is energy-intensive and requires specialized equipment, which limits its use to high-value products. Ongoing research examines how formulation and process parameters affect the quality of the final dried product.
Lyophilization, also known as freeze-drying, is a process that removes water from a material by freezing it and then reducing pressure to allow ice to sublimate directly into vapor. The method begins with a freezing step that solidifies the water content. Next, primary drying lowers the pressure below the triple point of water, enabling sublimation without passing through a liquid phase. A final secondary drying step removes bound water through desorption. This sequence produces a dry, porous cake that can be reconstituted later.
Handling and storage practices aim to keep the cake intact and dry. Vials are typically stored upright at controlled temperatures, often between 2 °C and 8 °C or at -20 °C for longer-term use. Reconstitution involves adding a suitable diluent and gently mixing until the solid dissolves. Shaking or rapid injection of diluent can create foam or damage sensitive molecules. Once reconstituted, the product may require refrigeration and use within a defined period.
Residual moisture is a key quality attribute for lyophilized products. Water that remains after secondary drying can affect chemical stability, cake structure, and shelf life. Karl Fischer titration is a common method for measuring water content in the dried solid. The target range varies by product, but many biologics are dried to between 0.5% and 3% water by weight. Acceptable limits are set during development and confirmed by stability studies.
Plasmids with specially-constructed features are commonly used in laboratory for cloning purposes. These plasmid are generally non-conjugative but may have many more features, notably a "multiple cloning site" where multiple restriction enzyme cleavage sites allow for the insertion of a transgene insert. The bacteria containing the plasmids can generate millions of copies of the vector within the bacteria in hours, and the amplified vectors can be extracted from the bacteria for further manipulation. Plasmids may be used specifically as transcription vectors and such plasmids may lack crucial sequences for protein expression. Plasmids used for protein expression, called expression vectors, would include elements for translation of protein, such as a ribosome binding site, start and stop codons.
=== Combination therapy === Combinations of finasteride, minoxidil, and ketoconazole are more effective than individual use. Combination therapy of LLLT or microneedling with finasteride or minoxidil demonstrated substantive increases in hair count.
1-hydroxy-2-naphthoate hydroxylase (EC 1.14.13.135, 1-hydroxy-2-naphthoic acid hydroxylase) is an enzyme with systematic name 1-hydroxy-2-naphthoate,NAD(P)H:oxygen oxidoreductase (2-hydroxylating, decarboxylating). This enzyme catalyses the following chemical reaction
As of 2017, lithium was marketed under many brand names worldwide, including Cade, Calith, Camcolit, Carbolim, Carbolit, Carbolith, Carbolithium, Carbonato de Litio, Carboron, Ceglution, Contemnol, Efadermin (Lithium and Zinc Sulfate), Efalith (Lithium and Zinc Sulfate), Elcab, Eskalit, Eskalith, Frimania, Hypnorex, Kalitium, Karlit, Lalithium, Li-Liquid, Licarb, Licarbium, Lidin, Ligilin, Lilipin, Lilitin, Limas, Limed, Liskonum, Litarex, Lithane, Litheum, Lithicarb, Lithii carbonas, Lithii citras, Lithioderm, Lithiofor, Lithionit, Lithium, Lithium aceticum, Lithium asparagicum, Lithium Carbonate, Lithium Carbonicum, Lithium Citrate, Lithium DL-asparaginat-1-Wasser, Lithium gluconicum, Lithium-D-gluconat, Lithiumcarbonaat, Lithiumcarbonat, Lithiumcitrat, Lithiun, Lithobid, Lithocent, Lithotabs, Lithuril, Litiam, Liticarb, Litijum, Litio, Litiomal, Lito, Litocarb, Litocip, Maniprex, Milithin, Neurolepsin, Plenur, Priadel, Prianil, Prolix, Psicolit, Quilonium, Quilonorm, Quilonum, Sedalit, Téralithe, and Theralite. Lithium is available as lithium carbonate in tablets or capsules, and as lithium citrate in liquid form. In the United States, standard release tablets are available in 300 mg. Standard release capsules come in strengths of 150 mg, 300 mg, and 600 mg. Slow release tablets are available in 300 mg and 450 mg. Liquid lithium, in the form of lithium citrate, is available as an 8 mEq/5 mL solution. In the United Kingdom, lithium is available as standard release tablets of 250 mg, while slow release tablets come in 200 mg, 400 mg and 450 mg.
Sources: en.wikipedia.org
=== Pharmacodynamics === Ritanserin acts as a selective 5-HT2A (Ki = 0.45 nM) and 5-HT2C receptor (Ki = 0.71 nM) antagonist. It has relatively low affinity for the H1, D2, α1-adrenergic, and α2-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT2A, respectively). The affinity of ritanserin for the 5-HT1A receptor is less than 1 μM. In addition to its affinity for the 5-HT2A and 5-HT2C receptors, ritanserin also binds to and antagonizes the 5-HT1D, 5-HT2B, 5-HT5A, 5-HT6, and 5-HT7 receptors. Ritanserin blocks c-RAF activation and induces apoptotic cell death of non–small cell lung cancer and small cell lung cancer cells.
The concept of Portal came from Narbacular Drop, a student project from the DigiPen Institute of Technology. The game included the aspects of placing portals on any flat surfaces and using them to maneuver around levels. Several Valve employees, attending a DigiPen career fair, saw Narbacular Drop and offered the entire team jobs at Valve almost immediately to help expand on their idea. Valve originally saw Portal as an experimental game to be included with its upcoming compilation, The Orange Box, alongside its release of Half-Life 2: Episode Two and Team Fortress 2. To give the game character, a minimal story, tied loosely with the Half-Life world, was written by Valve's Erik Wolpaw. He needed a character to guide the player through the game, coming onto a polite but humorous artificial intelligence, which would ultimately become the character of GLaDOS. Portal's release with The Orange Box received near-universal praise, with the standalone game earning an aggregate Metacritic rating of 90 out of 100. With success of the game, work on an expanded sequel began nearly immediately, expanding the development team from 8 to about 30-40 programmers. Initial ideas for Portal 2 retained the idea of solving puzzles through scientific concepts, but eliminating the use of portals altogether; these versions did not fare well with test audiences nor with Gabe Newell, Valve's president; these ideas were dropped though saved for potential reuse in a different game by Valve.
== Warnings/Precautions == Pancreatitis has been reported in clinical trials, do not continue usage if any pancreatitis has been spotted or confirmed, other therapies should be considered in patients with a prior history of pancreatitis Hypoglycemia has been noted when used in combination with an insulin secretagogue or insulin, consider lowering the usage of insulin in order to reduce the risk of hypoglycemia Hypersensitivity reactions such as anaphylactic reactions and angioedema have occurred; in this case discontinue Trulicity/dulaglutide and seek medical advice Acute kidney injury, monitor the renal function in patients with renal impairment and report severe gastrointestinal reactions Severe gastrointestinal disease, as usage may sometimes be associated with severe gastrointestinal reactions. (Source)
== Applications == This chemical similarity can be exploited in cancer, where a protein may mutate into an "always on" (constitutively active) state. A mutation may occur to replace a tyrosine (which needs to be phosphorylated in order to activate the protein) with an aspartic acid (which would not need to be phosphorylated). In a laboratory setting, the use of recombinant proteins to artificially introduce phosphomimetics is a common tool for studying phosphorylation and protein activation. For example, the IRF3 protein must be phosphorylated for its normal activity (transcription of its target genes, like IFNβ), but when serine amino acid residues were mutated to aspartic acid, the activity increased 90-fold. Phosphomimetics are commonly used in a gain of function experiment with respect to phosphorylation. For example, aspartate mutants were successfully used to probe the biological function of the phosphorylation of a threonine residue of a ribosomal protein both in vivo and in vitro to investigate a gain-of-function mutation on a kinase that is related to Parkinson's disease. Phosphomimetics were also used to investigate the therapeutic potential of proteins or peptides. For example, phosphomimetic mutants (using glutamate to mimic serine phosphorylation) have been used to demonstrate that the phosphorylated glycoproteins may have stronger anti-melanoma effects that the wildtype protein.
acid + base ⇌ conjugate base + conjugate acid. An acid is a proton donor; the proton is transferred to the base, a proton acceptor, creating a conjugate acid. For aqueous solutions of an acid HA, the base is water; the conjugate base is A− and the conjugate acid is the solvated hydrogen ion. In solution chemistry, it is usual to use H+ as an abbreviation for the solvated hydrogen ion, regardless of the solvent. In aqueous solution H+ denotes a solvated hydronium ion. The Brønsted–Lowry definition applies to other solvents, such as dimethyl sulfoxide: the solvent S acts as a base, accepting a proton and forming the conjugate acid SH+. A broader definition of acid dissociation includes hydrolysis, in which protons are produced by the splitting of water molecules. For example, boric acid, B(OH)3, acts as a weak acid, even though it is not a proton donor, because of the hydrolysis equilibrium
Sources: en.wikipedia.org
Lyophilization removes water by sublimation from a frozen material, while evaporation changes liquid water into vapor. The low-pressure freezing step avoids the liquid phase and can preserve heat-sensitive structures.
Vacuum lowers the pressure below the triple point of water, allowing ice to sublimate directly into vapor. It also helps remove water vapor from the product chamber and shortens primary drying.
Many aqueous solutions and suspensions can be freeze-dried, but some formulations collapse or do not form a stable cake. The process requires careful formulation and cycle development.
Collapse occurs when the product temperature rises above its collapse or eutectic temperature during drying. The frozen matrix loses structure, producing a shrunken or melted appearance. This can slow reconstitution and may affect stability.